Publications

Cancila V, Bertolazzi G, Chan ASy, Medico G, Bastianello G, Morello G, Paysan D, Lai C, Hong L, Shenoy G et al..  2025.  Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.. J Clin Invest. 135(18)

Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J et al..  2025.  EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.. Cancer Cell. 43(1):49-68.e9.

Hamid O, Cardin DB, F Hodi S, LoRusso P, Merghoub T, Zappasodi R, Maniyar R, Janik JE, van der Velden MVW, Zhou F et al..  2025.  First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.. Clin Cancer Res.

Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George MM, Thach D, Yao Z-K, Ouerfelli O, Liu H et al..  2024.  APR-246 increases tumor antigenicity independent of p53.. Life Sci Alliance. 7(1)

Li J, Chin CR, Ying H-Y, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu C-S, Jiang Y et al..  2024.  Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.. Nat Commun. 15(1):2879.

Verma S, Budhu S, Serganova I, Dong L, Mangarin LM, Khan JF, Bah MA, Assouvie A, Marouf Y, Schulze I et al..  2024.  Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.. J Clin Invest. 134(17)

Kang JHye, Zappasodi R.  2023.  Modulating Treg stability to improve cancer immunotherapy.. Trends Cancer. 9(11):911-927.

Kluger H, J Barrett C, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H et al..  2023.  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.. J Immunother Cancer. 11(3)

Davar D, Zappasodi R.  2023.  Targeting GITR in cancer immunotherapy - there is no perfect knowledge.. Oncotarget. 14:614-621.

Gregucci F, Spada S, Barcellos-Hoff MHelen, Bhardwaj N, Hak CChan Wah, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG et al..  2023.  Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.. Oncoimmunology. 12(1):2222560.

Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CCimen, Mangarin LMB, Redmond D, Verma S, Schad S et al..  2022.  Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.. Sci Transl Med. 14(649):eaba4380.

Huang AC, Zappasodi R.  2022.  A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.. Nat Immunol. 23(5):660-670.

Zappasodi R, Cook GP, Taylor A.  2022.  Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy.. Front Immunol. 13:1120207.

Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E.  2022.  Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer.. Front Oncol. 12:1061789.

Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KCésar, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR et al..  2022.  Fundamental immune-oncogenicity trade-offs define driver mutation fitness.. Nature. 606(7912):172-179.

Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A, Hammer C, Haymaker CL, Horak CE et al..  2022.  Hallmarks of Resistance to Immune-Checkpoint Inhibitors.. Cancer Immunol Res. 10(4):372-383.

Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, Samaan F, Ho Y-J, Campesato LFelipe, Mangarin L et al..  2022.  Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.. J Clin Invest. 132(18)

Andrlová H, Miltiadous O, Kousa AI, Dai A, DeWolf S, Violante S, Park H-Y, Janaki-Raman S, Gardner R, Daker SEl et al..  2022.  MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT.. Sci Transl Med. 14(646):eabj2829.

Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J et al..  2022.  Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.. Clin Cancer Res. 28(18):3990-4002.

He C, Maniyar RR, Avraham Y, Zappasodi R, Rusinova R, Newman W, Heath H, Wolchok JD, Dahan R, Merghoub T et al..  2022.  Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.. Sci Adv. 8(8):eabm4552.

Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M et al..  2022.  Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.. J Exp Med. 219(6)

Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, Watson MLJ, Leftin A, Maniyar R, Verma S et al..  2021.  CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.. Nature. 591(7851):652-658.

Serganova I, Chakraborty S, Yamshon S, Isshiki Y, Bucktrout R, Melnick A, Béguelin W, Zappasodi R.  2021.  Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.. Front Cell Dev Biol. 9:805195.

Fucà G, Ambrosini M, Agnelli L, Brich S, Sgambelluri F, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P et al..  2021.  Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells.. J Immunother Cancer. 9(6)

Alspach E, Chow RD, Demehri S, Guerriero JL, Gujar S, Hartmann FJ, Helmink BA, Hudson WH, Ho WJin, Ma L et al..  2021.  Supporting the Next Generation of Scientists to Lead Cancer Immunology Research.. Cancer Immunol Res. 9(11):1245-1251.